AKT1 and metabolic syndrome: Among these identified components, (−)-epicatechin 3-O-β-D-allopyranoside has been demonstrated to show anti-inflammatory activity [1], and prevent diabetes and dyslipidemia via alternation of the AMPK and Akt pathways exhibiting low cytotoxicity in the hosts [41,42].